Department of Dermatology, University of California Davis, Sacramento, California 95816, USA.
J Rheumatol. 2013 Aug;40(8):1438-41. doi: 10.3899/jrheum.130458.
At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) in Stockholm, Sweden, members addressed the infectious, oncologic, and autoimmune comorbidities of psoriasis and psoriatic arthritis (PsA). Members discussing infectious comorbidities asked whether patients with psoriasis or PsA are predisposed to particular types of infections, and whether the use of biologic agents is advisable in patients with certain preexisting infections. Regarding the oncologic comorbidities of psoriasis and PsA, members addressed cutaneous malignancy screening, lymphoproliferative malignancy risk and the need for screening, and treatment of patients with preexisting oncologic history requiring systemic therapy. Finally, GRAPPA members discussed autoimmune comorbidities associated with psoriasis and PsA; they agreed that research is nascent in this field and larger studies are necessary to determine the precise magnitude of these associations.
在瑞典斯德哥尔摩举行的 2012 年银屑病和银屑病关节炎研究与评估团体(GRAPPA)年会上,成员们讨论了银屑病和银屑病关节炎的传染性、肿瘤性和自身免疫性合并症。讨论传染性合并症的成员询问患有银屑病或银屑病关节炎的患者是否容易发生特定类型的感染,以及在患有某些预先存在的感染的患者中使用生物制剂是否明智。关于银屑病和银屑病关节炎的肿瘤合并症,成员们讨论了皮肤恶性肿瘤筛查、淋巴增生性恶性肿瘤风险和筛查的必要性,以及需要系统治疗的有预先存在肿瘤病史的患者的治疗。最后,GRAPPA 成员讨论了与银屑病和银屑病关节炎相关的自身免疫性合并症;他们一致认为该领域的研究尚处于起步阶段,需要进行更大规模的研究来确定这些关联的确切程度。